MV gliclazide

MV gliclazide – peroral hypoglycemic medicine.

Form of release and structure

MV gliclazide is produced in the form of tablets with the modified release: cylindrical, biconvex, white with a creamy shade or white color, existence of an insignificant mramornost is admissible (on 10, 20 or 30 pieces in planimetric aluminum or polyvinyl chloride strip packagings, on 1, 2, 3, 4, 5, 6, 10 packagings in a cardboard pack; on 10, 20, 30, 40, 50, 60 or 100 pieces in polymeric banks, after 1 bank in a cardboard pack).

Are a part of 1 tablet:

• Active agent: gliclazide – 30 mg;
• Auxiliary components: a gipromelloza – 70 mg; colloid silicon dioxide – 1 mg; microcrystallic cellulose – 98 mg; magnesium stearate – 1 mg.

Indications to use

MV gliclazide is appointed for moderately severe treatment of a diabetes mellitus by 2 types (non-insulin-dependent) with initial manifestations of a diabetic mikroangiopatiya.

Also drug is used for prevention of disturbances of microcirculation (along with other derivatives of sulphonylurea).

Contraindications

• Diabetes mellitus of the 1st type (insulin-dependent);
• The expressed functional disturbances of a liver and kidneys;
• Ketoacidosis;
• Diabetic coma and prekoma;
• Simultaneous use with imidazole derivatives (including Miconazolum);
• Hypersensitivity to streptocides and derivatives of sulphonylurea.

Use of MV Gliclazide is not recommended to the feeding and pregnant women.

Route of administration and dosage

MV gliclazide is accepted inside before food.

Frequency rate of administration of drug – 2 times a day.

The doctor defines a daily dose individually, based on clinical displays of a disease and glycemia, on an empty stomach and 2 hours later after food.

As a rule, the initial dose makes 80 mg a day, an average dose – 160-320 mg a day.

Side effects

During use of MV Gliclazide development of disturbances from some systems of an organism is possible:

• Alimentary system: seldom – nausea, anorexia, diarrhea, vomiting, pains in the area epigastriums;
• Endocrine system: at overdose – a hypoglycemia;
• System of a hemopoiesis: in some cases – thrombocytopenia, a leukopenia or an agranulocytosis, anemia (usually reversible character);
• Allergic reactions: itch, skin rash.

Special instructions

At treatment of a non-insulin-dependent diabetes mellitus MV Gliclazide should be applied along with a low-calorie diet with the small content of carbohydrates.

During therapy it is regularly necessary to control daily fluctuations of level of glucose, and also glucose level in blood on an empty stomach and after meal.

At surgical interventions or a decompensation of a diabetes mellitus it is necessary to consider a possibility of use of drugs of insulin.

In case of development of a hypoglycemia if the patient is in consciousness, glucose (or sugar solution) should be applied inside. At a loss of consciousness it is necessary to enter glucose (intravenously) or a glucagon (subcutaneously, intramusculary or intravenously). In order to avoid repeated development of a hypoglycemia after consciousness recovery the patient needs to give carbohydrate-rich food.

Simultaneous use of gliclazide with Cimetidinum is not recommended.

At combined use of gliclazide with verapamil it is regularly necessary to control glucose level in blood; with acarbose – careful control and correction of the mode of dosing of hypoglycemic means is necessary.

Medicinal interaction

At combined use of MV Gliclazide with some medicines there can be undesirable effects:

• Pyrazyl ketone derivatives, salicylates, phenylbutazone, antibacterial sulfanamide drugs, theophylline, caffeine, monoamine oxidase inhibitors (MAO): potentiation of hypoglycemic effect of gliclazide;
• Non-selective beta adrenoblockers: increase in probability of emergence of a hypoglycemia, is also possible strengthening of perspiration and masking characteristic of a hypoglycemia of tachycardia and a tremor of hands;
• Gliclazide and acarbose: strengthening of hypoglycemic effect;
• Cimetidinum: increase in concentration of gliclazide in plasma (development of the heavy hypoglycemia which is shown in the form of oppression of the central nervous system and disturbance of consciousness is possible);
• Glucocorticosteroids (including outside dosage forms), the diuretics, barbiturates, estrogen, progestin combined it is oestrogenic-gestagennye drugs, dipheninum, rifampicin: decrease in hypoglycemic effect of gliclazide.

Terms and storage conditions

To store in protected from light, the place, unavailable to children, at a temperature up to 25 °C.

Period of validity – 3 years.